Public market insider selling at Mydecine Innovations (C:MYCO)

Michael Connolly, a Director, disposed of 2,058,298 Common Shares on a direct ownership basis at prices ranging from $0.540 to $0.600 between February 16th, 2021 and February 18th, 2021. This represents a $1,174,979 divestment of the company's shares and an account share holdings change of -100.0%.

Mydecine Innovations is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

Mydecine Innovations Group Inc. is a Canada-based biopharma and life sciences company. The Company is focused on the research, development and acceptance of alternative nature-sourced medicine. Its portfolio of companies includes Mydecine Health Sciences (MHS), Mindleap Health Inc. (Mindleap) and NeuroPharm, Inc (NPI). MHS is focused on developing fungtional mushroom products and psychedelic medicines for the consumer and professional healthcare market. NPI is a veterans-focused healthcare company that is developing pharmaceutical and natural health products for mental wellness in vulnerable populations, including veterans, emergency medical services (EMS) personnel and other high-risk constituencies. NPI is developing psilocybin-assisted psychotherapy to treat chronic post-traumatic stress disorder (PTSD). Mindleap offers a digital health platform that enables people connect with mental health specialists, who can help them to develop habits for a healthy mind.